Co-Diagnostics (CODX) Stock Price, News & Analysis

Company Overview

Co-Diagnostics, Inc. is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services. During the COVID-19 pandemic, the company rapidly developed and obtained regulatory approvals for several SARS-CoV-2 detection kits, expanding its product portfolio to cover multiple viral targets and multiplexed testing formats. Beyond COVID-19, Co-Diagnostics has pursued assay development across areas such as tuberculosis, Zika virus, HIV, human papillomavirus (HPV) and oncogene mutations, aiming to address diagnostic needs in both clinical laboratories and point-of-care settings.

Co-Diagnostics maintains a global distribution network spanning North America, Latin America, Europe, Africa and parts of the Asia-Pacific region. The company sells its products under direct supply agreements as well as through regional partners, enabling a broad geographic reach. Co-Diagnostics went public in June 2020 and is listed on the Nasdaq Global Market under the ticker symbol CODX. Leadership is anchored by co-founder and Chief Executive Officer Douglas K. Bryant, who oversees research and development, while a management team with expertise in molecular biology, regulatory affairs and commercial operations drives the company’s strategic growth initiatives.

Key Stats

• Today's Range: $0.31 to $0.32
• 50-Day Range: $0.25 to $0.34
• 52-Week Range: $0.23 to $1.40
• Volume: 256,539 shs
• Average Volume: 1.02 million shs
• Market Capitalization: $12.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Buy

Co-Diagnostics Stock Analysis - MarketRank™

Co-Diagnostics scored higher than 82% of companies evaluated by MarketBeat, and ranked 191st out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Co-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Co-Diagnostics has a consensus price target of $5.50, representing about 1,651.6% upside from its current price of $0.31.

Amount of Analyst Coverage

Co-Diagnostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Co-Diagnostics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Co-Diagnostics is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Co-Diagnostics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.33% of the outstanding shares of Co-Diagnostics have been sold short.

Short Interest Ratio / Days to Cover

Co-Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Co-Diagnostics has recently decreased by 14.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Co-Diagnostics does not currently pay a dividend.

Dividend Growth

Co-Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.10

Percentage of Shares Shorted

1.33% of the outstanding shares of Co-Diagnostics have been sold short.

Short Interest Ratio / Days to Cover

Co-Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Co-Diagnostics has recently decreased by 14.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Co-Diagnostics this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for CODX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

2 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Co-Diagnostics is held by insiders.

Percentage Held by Institutions

Only 14.99% of the stock of Co-Diagnostics is held by institutions.

CODX Stock Analysis - Frequently Asked Questions

How have CODX shares performed this year?

Co-Diagnostics' stock was trading at $0.75 at the beginning of the year. Since then, CODX shares have decreased by 58.1% and is now trading at $0.3140.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) posted its quarterly earnings results on Thursday, August, 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.30 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 69.49% and a negative net margin of 3,588.33%.
Read the conference call transcript.

When did Co-Diagnostics IPO?

Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.

Who are Co-Diagnostics' major shareholders?

Top institutional investors of Co-Diagnostics include Jane Street Group LLC (0.50%).
View institutional ownership trends.

How do I buy shares of Co-Diagnostics?

Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/09/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CODX
• CIK: 1692415
• Web: www.codiagnostics.com
• Phone: (801) 438-1036
• Fax: N/A
• Employees: 100
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Co-Diagnostics: $5.50
• High Price Target: $10.00
• Low Price Target: $1.00
• Potential Upside/Downside: +1,650.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.64 million
• Net Margins: -3,588.33%
• Pretax Margin: -3,584.55%
• Return on Equity: -69.49%
• Return on Assets: -60.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.12
• Quick Ratio: 3.83

Sales & Book Value

• Annual Sales: $3.91 million
• Price / Sales: 3.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.70 per share
• Price / Book: 0.18

Miscellaneous

• Outstanding Shares: 38,520,000
• Free Float: 36,174,000
• Market Cap: $12.10 million
• Optionable: Optionable
• Beta: 0.78